TreatmentJuly 16, 2020
The New Normal for Treating Moderate-to-Severe Plaque Psoriasis
Hear George Han, M.D. of the Icahn School of Medicine at Mt. Sinai, and Mark Kaufmann, M.D., President-Elect at the American Academy of Dermatology, discuss the new normal for dermatologists and learn about ILUMYA™ (tildrakizumab-asmn), a treatment for moderate-to-severe plaque psoriasis.
This podcast episode is sponsored by Sun Pharma.